Acupuncture for Depression: Sigma-1 Receptor-Related Brain Network Modulation
A Study on the Effects of Acupuncture in Treating Depression: Sigma-1 Receptor-Targeted pBFS for Individualized Brain Network Regulation and Prediction of Treatment Outcomes
This study will compare two types of acupuncture for adults with mild to moderate depression. One group will receive acupuncture. The other group will receive pivot acupuncture, a technique that uses needles at points on the head and neck. Participants with depression will be assigned to one of the two groups by chance. Both groups will attend three sessions a week for six weeks.
The researchers will compare how many people in each group have a substantial improvement in their depression symptoms by the end of treatment. They will also use brain scans and blood tests to examine whether symptom improvement is related to changes in how different parts of the brain work together and to changes in blood levels of a protein called the sigma-1 receptor.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
In this parallel-group randomized trial, 72 adults with a mild to moderate depressive episode will be assigned in a 1:1 ratio to acupuncture or pivot acupuncture. The allocation sequence will be generated using SAS and concealed in sequentially numbered, opaque, sealed envelopes until treatment assignment.
Structural brain MRI, resting-state functional MRI, and peripheral blood sampling will be performed at baseline and at the end of the six-week treatment period. The personalized brain functional sectors (pBFS) method will be used to define 92 functional brain regions for each participant and estimate pairwise functional connectivity. The investigators will examine associations among changes in connectivity, peripheral sigma-1 receptor levels, and depressive symptoms. They will also explore whether changes in connectivity can estimate the magnitude of symptom improvement and compare models based on individualized and group-level brain maps.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Xinjing Yang, Doctor
- Phone Number: 86+18813989594
- Email: yangxinjing120@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 to 60 years, inclusive.
- Right-handed.
- Diagnosed with a depressive episode according to ICD-10 code F32 and meeting DSM-5 criteria for a depressive episode.
- Mild to moderate depressive symptoms, defined as a baseline score of at least 8 and less than 24 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
- No use of immunomodulators, antidepressants, or other medications that affect mood in the month before enrollment.
- Willing and able to follow study procedures and provide written informed consent.
Exclusion Criteria:
- Another psychiatric disorder, such as bipolar disorder or schizophrenia.
- Autoimmune disease or acute infection.
- Intellectual disability (IQ below 70) or autism spectrum disorder.
- History of epilepsy or a brain lesion.
- History of drug dependence.
- A contraindication to acupuncture, electroacupuncture, or MRI, such as an infectious condition that precludes needling, a history of fainting with needling, claustrophobia, or an MRI-incompatible intracranial implant.
- Suicide risk identified at screening.
- Current participation in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Acupuncture
Participants will receive acupuncture three times a week for six weeks, for a total of 18 sessions. Each session will last 30 minutes. |
The primary points are Baihui (GV20) and Yintang. Baihui is needled transversely from anterior to posterior to a depth of 0.5-0.8 cun. Yintang is needled slowly in a superior direction to a depth of 0.5-0.8 cun and gently rotated to de qi. Additional points are Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), Zusanli (ST36), and Taichong (LR3). Sterile acupuncture needles measuring 0.30 × 25 mm or 0.30 × 40 mm are used. Qualified practitioners with at least five years of clinical experience administer treatment. |
|
Active Comparator: Pivot Acupuncture
Participants will receive pivot acupuncture three times a week for six weeks, for a total of 18 sessions. Needles will be retained for 20 minutes at each session. |
Needles are placed at Fengfu (GV16), Naohu (GV17), and bilateral Fengchi (GB20), Tianzhu (BL10), Wangu (GB12), Yifeng (TE17), Tianyou (TE16), and Anmian. With participants supine, the skin is disinfected with 75% alcohol. Sterile, single-use Huanqiu needles (Suzhou Huanqiu Acupuncture Medical Appliance Co., Ltd., China), 0.30 × 25 mm or 0.30 × 40 mm, are inserted rapidly. Fengchi is needled obliquely toward the tip of the nose to a depth of 10-23 mm. Fengfu is needled straight toward the mandible to a depth of 10-23 mm. Naohu is needled obliquely downward to a depth of 23 mm. Tianzhu, Wangu, Yifeng, Tianyou, and Anmian are needled perpendicularly to a depth of 30 mm. Needles are manipulated by lifting, thrusting, and rotating, then retained for 20 minutes. Treatment is administered without electrical stimulation. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With a Clinical Response on the HAMD-17
Time Frame: Baseline and Week 6 (end of treatment).
|
Clinical response is defined as a reduction of at least 50% from baseline in the total score on the 17-item Hamilton Depression Rating Scale (HAMD-17). The HAMD-17 is a clinician-rated measure of depressive symptom severity. Total scores range from 0 to 52, with higher scores indicating more severe symptoms. |
Baseline and Week 6 (end of treatment).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants in Remission on the HAMD-17
Time Frame: Week 6 (end of treatment).
|
Remission is defined as a total score below 8 on the 17-item Hamilton Depression Rating Scale (HAMD-17). |
Week 6 (end of treatment).
|
|
Change From Baseline in HAMD-17 Total Score
Time Frame: Baseline and Week 6 (end of treatment).
|
The Week 6 total score minus the baseline total score on the 17-item Hamilton Depression Rating Scale. Total scores range from 0 to 52, with higher scores indicating more severe symptoms. A negative change indicates improvement. |
Baseline and Week 6 (end of treatment).
|
|
Change From Baseline in SF-12 Summary Score
Time Frame: Baseline and Week 6 (end of treatment).
|
The 12-Item Short Form Health Survey (SF-12) is a self-reported measure of health status. Higher scores indicate better physical health. Change is calculated as the Week 6 score minus the baseline score. |
Baseline and Week 6 (end of treatment).
|
|
Change From Baseline in BC-CCI-E Cognitive Complaints Score
Time Frame: Baseline and Week 6 (end of treatment).
|
The British Columbia Cognitive Complaints Inventory-Expanded (BC-CCI-E) is a self-report measure of perceived cognitive difficulties. Higher cognitive complaints scores indicate more severe difficulties. Change is calculated as the Week 6 score minus the baseline score. |
Baseline and Week 6 (end of treatment).
|
|
Suicide risk monitoring
Time Frame: From enrollment through Week 10
|
Suicide risk will be assessed at baseline and weekly during the six-week treatment period using the Columbia-Suicide Severity Rating Scale (C-SSRS). |
From enrollment through Week 10
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With at Least One Adverse Event
Time Frame: From enrollment through Week 10
|
Adverse events will be recorded from enrollment through the final follow-up visit. The number and percentage of randomized participants with at least one adverse event will be summarized by treatment group. |
From enrollment through Week 10
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NO.JCYJ20250604191311016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.